The Guinea Pig Model : An Alternative Method for Vaccine Potency Testing book cover
SAVE
$9.99
1st Edition

The Guinea Pig Model
An Alternative Method for Vaccine Potency Testing




  • Available for pre-order on March 14, 2023. Item will ship after April 4, 2023
ISBN 9780367489861
April 4, 2023 Forthcoming by CRC Press
224 Pages 7 Color & 30 B/W Illustrations

FREE Standard Shipping
 
SAVE $9.99
was $49.95
USD $39.96

Prices & shipping based on shipping country


Preview

Book Description

This book summarizes the development and statistical validation of a guinea pig model as an alternative for potency testing of the viral antigens included in combined vaccines applied in cattle to control the respiratory, reproductive, and neonatal calf diarrhea syndromes. The model allows, in one serum sample, to test the vaccine quality for all the viral antigens included in aqueous as well as in oil-adjuvanted formulations of bovine vaccines. The methodology proposed for the control of bovine herpes virus, parainfluenza, and rotavirus were recommended by CAMEVET as guidelines for the 30 countries in the forum, including the US.

Key Features

  • Reviews combined vaccines used for cattle
  • Summarizes animal models used for vaccine testing
  • Focuses on bovine herpesviruses, rotaviruses, parainfluenza, and bovine viral diarrhea virus
  • Provides guidance on the effectiveness of the Guinea Pig model for testing vaccine immunogenicity

Table of Contents

Chapter 1 - Vaccination of cattle

Chapter 2 - Guinea pig model to test the potency of IBR vaccines

Chapter 3 - Guinea pig model to test the potency of Rotavirus vaccines

Chapter 4 - Guinea pig model to test the potency of Bovine Parainfluenza Type 3 Virus vaccines

Chapter 5 - Guinea pig model to test the potency of BVDV vaccines

Chapter 6 - Guinea pig model application

References

...
View More

Author(s)

Biography

Viviana Parreño, Biochemist (1995), Ph.D. in Veterinary Virology and Immunology (2002) and Master in Biometrics (2021), works since 1992 at The National Institute of Agricultural Technology, INTA, Argentina and is a member of CONICET scientific career since 2007. At the moment of writing the present book Dr Parreño is working as Visiting Research scientist at the Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University from July 2021-October 2022.

Dr Parreño was in charge of the VD-Lab (viral gastroenteritis lab) at the Virology Institute, INTA from 2004 to 2016. She has 30 years of research experience, including epidemiological studies of animal rotavirus, coronavirus and norovirus; development of vaccines and passive immune strategies to prevent calf and foal diarrhea; development of calf models of bovine rotavirus and coronavirus infection and disease; and development and characterization of llama derived-nanobodies; development and statistical validation of diagnosis kits including Rotadial, the first nanobody-based kit used in the hospitals of the acute diarrhea surveillance network of the Argentinean Ministry of health (INEI-ANLIS Malbran).

Dr. Parreño is co-founder and scientific coordinator of INCUINTA (2009 to present), the incubator of biotechnological platforms of INTA. She is one of the entrepreneurs who created of the public-private startup company BIOINNOVO (INTA-Vetanco S.A.) and participated actively in the development of three veterinary products in the market: Rotacoli Equina® Biochemic; BIOINNOVO IgY DNT® an IgY-based product to prevent calf diarrhea by RVA, Coronavirus, E coli and Salmonella and VEDEVAX®,a BVDV subunit targeted vaccine).

Starting from 2003 to present, Dr Parreno coordinated a large team of researchers and private partners to reach the development and statistical validation of the INTA guinea pig model for potency testing of bovine viral vaccines, the topic of this present book. The model was adopted as the official potency control test of vaccines administered to cattle in Argentina (SENASA- Animal Health Service Resol. 598.12), and it is expected to extend its use through CAMEVET and the World Organisation for Animal Health at a regional and worldwide level.